NOVO

Prime Minister Narendra Modi met with Russian President Vladimir Putin at the Novo-Ogaryovo state residence, a day after arriving in Moscow amid global criticism of Russian strikes in Ukraine. Here are some photos from their meeting.

Wockhardt's Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk's Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.

A new weekly insulin dosage by Novo Nordisk, Insulin Icodec, is on the brink of approval in India, offering potential relief for those who require daily insulin injections. The Subject Expert Committee has recommended permitting the import and sale ...

This expertly curated article offers a treasure trove of engaging options designed to captivate your toddlers' imaginations. From playset that foster cognitive growth to cute little soft dolls that ensure comfort and joy, our selection caters to eve...

Novo Nordisk's India team played a pivotal role in the success of Ozempic, a semaglutide-based drug for diabetes and weight management. The Bengaluru-based Global Business Services unit collaborated on clinical trials and biostatistics. Despite glob...

In new forecasts, the ECB said it expected inflation to average 2.2% in 2025 - up from a previous estimate of 2.0% and meaning it was now seen holding above the central bank's 2% target well into next year. ECB President Christine Lagarde said that ...

NUMAB THERAPEUTICS-JOHNSON&JOHNSON/M&A (UPDATE 2, PIX)UPDATE 2-J&J acquires experimental skin disorder drug for $1.25 billion

A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis, characterized by delayed stomach emptying. The study, presented at Digestive Disease Week 2024, indicates a 30% higher ris...

A massive fire broke out at a Novo Nordisk office building in Copenhagen, prompting the evacuation of all occupants. Around 100 firefighters worked to extinguish the blaze that spread from a construction site to an adjacent building. There were no i...

A new analysis highlights the significant cardiovascular benefits of Novo Nordisk's obesity drug Wegovy, showing improvements regardless of weight loss amount. This challenges perceptions of GLP-1 drugs, suggesting they could be viewed more as heart...

Managing type 2 diabetes involves crucial lifestyle changes for blood sugar control, mental health support, weight management, nutrition therapy, stress management, physical activity, and glucose regulation.

India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenges and evolving disease patterns as it grows as a superpower.

KKR acquired Healthium Medtech Ltd., a leading Indian medical devices company, from Apax Partners. The deal, valued at approximately Rs 7000 crore, involves a special purpose vehicle owned by KKR-managed funds gaining control of Healthium. Healthium...

Binding agreement signed; formal announcement by early next week, pips rival bidders Mankind Pharma-Chrys Cap Healthium is the largest manufacturer of surgical needles globally by volume.

Novo Holdings, the investment arm of the Novo Nordisk Foundation, has 77% of voting shares in Novo Nordisk, which is known for producing blockbuster obesity drug Wegovy and diabetes treatment Ozempic.

Doctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resort for some. “I would rather go for these short cuts that the pharma industry offers than go under the knife fo...

Novo Nordisk A/S bought Cardior Pharmaceuticals for $1 billion to enhance cardiovascular treatments. Cardior's microRNA-targeting therapies aim to improve heart function, aligning with Novo's focus on diabetes and obesity history.

Novo Holdings is the latest challenger in a hotly contested bidding process for Healthium, 99.8% owned by Apax Partners. Buyout funds KKR, Hillhouse, EQT, Blackstone and TA Associates among others have already been shortlisted after the initial roun...

AstraZeneca announced its acquisition of Amolyt Pharma, a company focused on endocrine diseases, for $1.05 billion in cash. This move aims to strengthen AstraZeneca's rare diseases portfolio. Amolyt Pharma, based in France, is in the late-stage deve...